Company profile: Armata Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of bacteriophage-based therapeutics, including AP-PA02 for Pseudomonas aeruginosa respiratory infections, AP-SA02 for drug-resistant Staphylococcus aureus (MRSA/VRSA), and AP-PA03 for P. aeruginosa pneumonia, plus a proprietary synthetic phage engineering platform, phage discovery and phenotyping, and bioinformatics-enabled phage analyses to enhance efficacy.
Products and services
- Synthetic Phage Program: Proprietary platform that engineers bacteriophages to expand host range and disrupt biofilms, enhancing clinical efficacy for targeted therapeutics
- AP-PA02: Bacteriophage cocktail targeting Pseudomonas aeruginosa, developed to treat respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasis patients
- AP-SA02: Biologic product comprising natural lytic phages against Staphylococcus aureus, aimed at treating drug-resistant infections, including MRSA and VRSA
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Armata Pharmaceuticals
MSD
HQ: United States
Website
- Description: Provider of medicines, vaccines, biologic therapies, and animal health products as a leading global biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MSD company profile →
Prosetta Biosciences
HQ: United States
Website
- Description: Provider of the Prosetta Platform, a drug discovery platform applying small molecules that modulate assembly of multi-protein complexes for infectious and degenerative diseases. Offers antiviral compounds targeting energy-dependent capsid assembly, an oncology program identifying anti-proliferative agents across ~75 cancers, antibacterial and neurodegenerative research, and PAV-431, a host-targeted antiviral effective against multiple respiratory viruses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prosetta Biosciences company profile →
Bioquell
HQ: United Kingdom
Website
- Description: Provider of biodecontamination systems and services specializing in Hydrogen Peroxide Vapor technology to eliminate bacteria, viruses, fungi, and spores. Products include Bioquell Hydrogen Peroxide Vapour Decontamination (35% H2O2 vapor for surface and airborne pathogen elimination), Rapid Bio-Decontamination Service, ProteQ automated room decontamination, and Qube isolators for sterility testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioquell company profile →
Cempra
HQ: United States
Website
- Description: Provider of medicines for the treatment of bacterial infections and chronic illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cempra company profile →
OLM Diagnostics
HQ: United Kingdom
Website
- Description: Provider of fungal and bacterial diagnostic solutions for healthcare providers, including: AspLFD, a lateral flow device detecting Aspergillus antigens in 15–40 minutes; AspID and PneumID real-time PCR kits for Aspergillus species (90 minutes) and Pneumocystis jirovecii (45 minutes); CandID for early Candida bloodstream detection; and AurisID for identifying Candida auris.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OLM Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Armata Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Armata Pharmaceuticals
2.2 - Growth funds investing in similar companies to Armata Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Armata Pharmaceuticals
4.2 - Public trading comparable groups for Armata Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →